ConductScience.org, home

Paper3125883

Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.

Br Med J (Clin Res Ed), 1988. Cited by 132 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Papers, record 3125883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3125883

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
PubMed
Journal
Br Med J (Clin Res Ed)
PubMed
Year
1988
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
132
iCite
Relative citation ratio, by iCite
4.11
iCite
Revised in PubMed
2022-03-30
PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angina PectorisMajor topic
Angina, UnstableMajor topic
Cerebrovascular DisordersMajor topic
Myocardial InfarctionMajor topic
Platelet Aggregation InhibitorsMajor topic
Aspirin
Dipyridamole
Drug Combinations
Humans
Prognosis
Random Allocation
Sulfinpyrazone

Source PubMed

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14,885,615Controlled trial of dipyridamole in cerebral vascular disease.Br Med J1969https://conductscience.org/library/papers/4885615PubMed
23,317,048Current medical and surgical therapy for cerebrovascular disease.N Engl J Med1987https://conductscience.org/library/papers/3317048PubMed
31,105,880Proceedings: The effect of a platelet inhibiting drug (sulfinpyrazone) in the therapy of patients with transient ischemic attacks (Tia's) and minor strokes.Thromb Diath Haemorrh1975https://conductscience.org/library/papers/1105880PubMed
4324,036Controlled trial of aspirin in cerebral ischemia.Stroke1977https://conductscience.org/library/papers/324036PubMed
5354,098Controlled trial of aspirin in cerebral ischemia. Part II: surgical group.Stroke1978https://conductscience.org/library/papers/354098PubMed
692,668Aspirin and secondary mortality after myocardial infarction.Lancet1979https://conductscience.org/library/papers/92668PubMed
77,005,035Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.Haemostasis1980https://conductscience.org/library/papers/7005035PubMed
87,027,408["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].Rev Neurol (Paris)1981https://conductscience.org/library/papers/7027408PubMed
97,039,004A randomized trial of aspirin and sulfinpyrazone in patients with TIA.Stroke1982https://conductscience.org/library/papers/7039004PubMed
106,815,756[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].Rev Neurol (Paris)1982https://conductscience.org/library/papers/6815756PubMed
116,337,425Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study.Stroke1983https://conductscience.org/library/papers/6337425PubMed
126,401,878"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.Stroke1983https://conductscience.org/library/papers/6401878PubMed
136,345,461Aspirin in coronary heart disease. Comparison of six clinical trials.Isr J Med Sci1983https://conductscience.org/library/papers/6345461PubMed
146,367,153Prolongation of bleeding time and inhibition of platelet aggregation by low-dose acetylsalicylic acid in patients with cerebrovascular disease.Stroke1984https://conductscience.org/library/papers/6367153PubMed
156,144,975Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation.Lancet1984https://conductscience.org/library/papers/6144975PubMed
166,745,127Aspirin in the prevention of myocardial infarction. Current status.Drugs1984https://conductscience.org/library/papers/6745127PubMed
176,385,651The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics.Agents Actions Suppl1984https://conductscience.org/library/papers/6385651PubMed
186,385,653Canadian American ticlopidine study (cats) in thromboembolic stroke.Agents Actions Suppl1984https://conductscience.org/library/papers/6385653PubMed
192,858,114Beta blockade during and after myocardial infarction: an overview of the randomized trials.Prog Cardiovasc Dis1985https://conductscience.org/library/papers/2858114PubMed
202,988,158A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke.Stroke1985https://conductscience.org/library/papers/2988158PubMed

See all 32 references

Cited by112

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.

PMIDTitleJournalYearIn PapersSource
41,774,848[Anatomy of the Forest Plot graphic].Rev Med Inst Mex Seguro Soc2026https://conductscience.org/library/papers/41774848PubMed
41,702,715Research Waste, Redundancy and the Rise of the Machines: The Questionable Future of Systematic Reviews.Drug Alcohol Rev2026https://conductscience.org/library/papers/41702715PubMed
40,910,165Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.Circulation2025https://conductscience.org/library/papers/40910165PubMed
40,769,693Oral Anticoagulant Management for Peripheral Vascular Disease.Adv Surg2025https://conductscience.org/library/papers/40769693PubMed
40,491,717Methods and validity indicators for measuring adherence and persistence to aspirin in secondary cardiovascular prevention: a systematic review.Front Cardiovasc Med2025https://conductscience.org/library/papers/40491717PubMed
39,763,632Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a).Drugs Context2024https://conductscience.org/library/papers/39763632PubMed
39,064,188Aspirin in Primary Prevention: Looking for Those Who Enjoy It.J Clin Med2024https://conductscience.org/library/papers/39064188PubMed
38,791,515
Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y12 Antagonists and Interference with Inflammation and NLRP3 Assembly.
Int J Mol Sci2024https://conductscience.org/library/papers/38791515PubMed
38,784,152Controversy in cardiology: clopidogrel or acetylsalicylic acid in the treatment of chronic coronary syndromes?Eur Heart J Suppl2024https://conductscience.org/library/papers/38784152PubMed
37,622,482Ischaemic stroke despite antiplatelet therapy: Causes and outcomes.Eur Stroke J2023https://conductscience.org/library/papers/37622482PubMed
34,824,680Aspirin in the Modern Era of Cardiovascular Disease Prevention.Methodist Debakey Cardiovasc J2021https://conductscience.org/library/papers/34824680PubMed
30,773,981Reflections on the design and analysis of clinical trials and meta-analyses in the 1970s and 1980s.J R Soc Med2019https://conductscience.org/library/papers/30773981PubMed
30,505,394Effect of Sociodemographic Variables and Other Factors on the Usage of Different Doses of Aspirin in Postmyocardial Infarction Patients: A Cross-sectional Study.Heart Views2018https://conductscience.org/library/papers/30505394PubMed
30,368,251Partially systematic thoughts on the history of systematic reviews.Syst Rev2018https://conductscience.org/library/papers/30368251PubMed
29,236,147[Platelet inhibition in elderly patients].Herz2018https://conductscience.org/library/papers/29236147PubMed
28,403,216Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.PLoS One2017https://conductscience.org/library/papers/28403216PubMed
28,360,907Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.Front Immunol2017https://conductscience.org/library/papers/28360907PubMed
27,482,236Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013.Arch Med Sci2016https://conductscience.org/library/papers/27482236PubMed
27,423,939The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.Curr Cardiol Rep2016https://conductscience.org/library/papers/27423939PubMed
27,059,906History of evidence synthesis to assess treatment effects: Personal reflections on something that is very much alive.J R Soc Med2016https://conductscience.org/library/papers/27059906PubMed

See all 112 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3125883

GET https://conductscience.org/api/papers/v1/3125883/references?page=2